ArticleBritish journal of cancer2020
Ibrutinib treatment inhibits breast cancer progression and metastasis by inducing conversion of myeloid-derived suppressor cells to dendritic cells.
Article in British journal of cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
53 citing papers in PubMed, 1 synthesis or guideline pooled it, 71 citations in OpenAlex.
- Ibrutinib in Gynecological Malignancies and Breast Cancer: A Systematic Review.International journal of molecular sciences · 2020Pooled it
- A Phase I/II Study of Ibrutinib Plus Trastuzumab in HER2-Positive Metastatic Breast Cancer.Cancer medicine · 2026Trial
- Bruton's Tyrosine Kinase Inhibitors: Mechanisms, Efficacy, Toxicities and Applications for the Treatment of Human Diseases.MedComm · 2026Review
- Advances in the design and discovery of small-molecule tyrosine kinase inhibitors for breast cancer.RSC advances · 2026Review
- Expression of Bruton's Tyrosine Kinase Reflects Immune Cells Infiltration and Cell Proliferation in Breast Cancer.World journal of oncology · 2026Article
- Letter to the Editor: Combination of FTO and BTK inhibitors synergistically suppresses the malignancy of breast cancer cells.International journal of biological sciences · 2026Article
- MDSCs in Breast Cancer: Metastasis, Lipid Metabolism, and Therapeutics.Molecular cancer research : MCR · 2025Review
- Inhibition of head and neck squamous cell carcinoma by Bruton's tyrosine kinase inhibitor ibrutinib is associated with reduction of immunosuppressive T cells.Cancer immunology, immunotherapy : CII · 2025Article
- The immunosuppressive role of MDSCs in HCC: mechanisms and therapeutic opportunities.Cell communication and signaling : CCS · 2025Review
- Yiai Fuzheng decoction inhibits triple-negative breast cancer by remodeling the immune microenvironment.Frontiers in immunology · 2025Article
- Computational molecular insights into ibrutinib as a potent inhibitor of HER2-L755S mutant in breast cancer: gene expression studies, virtual screening, docking, and molecular dynamics analysis.Frontiers in molecular biosciences · 2025Article
- Combination of FTO and BTK inhibitors synergistically suppresses the malignancy of breast cancer cells.International journal of biological sciences · 2025Article
- Immune Microenvironment in Breast Cancer Metastasis.Advances in experimental medicine and biology · 2025Review
- Activated B cells modulate the maturation of MDSCs via CD36-dependent MHC-II transfer to orchestrate CD4International journal of biological sciences · 2025Article
- Inhibition of Bruton's tyrosine kinase with PD-1 blockade modulates T cell activation in solid tumors.JCI insight · 2024Article
- Multifunctional Nanovaccine Sensitizes Breast Cancer to Immune Checkpoint Therapy.Advanced functional materials · 2024Article
- MDSC expansion during HIV infection: regulators, ART and immune reconstitution.Genes and immunity · 2024Review
- MMDRP: drug response prediction and biomarker discovery using multi-modal deep learning.Bioinformatics advances · 2024Article
- Study on the mechanism of MDSC-platelets and their role in the breast cancer microenvironment.Frontiers in cell and developmental biology · 2024Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundIbrutinib is a Bruton's tyrosine kinase (BTK) and interleukin-2-inducible kinase (ITK) inhibitor used for treating chronic lymphocytic leukaemia (CLL) and other cancers. Although ibrutinib is known to inhibit the growth of breast cancer cell growth in vitro, its impact on the treatment and metastasis of breast cancer is unclear.
methodsUsing an orthotopic mouse breast cancer model, we show that ibrutinib inhibits the progression and metastasis of breast cancer.
resultsIbrutinib inhibited proliferation of cancer cells in vitro, and Ibrutinib-treated mice displayed significantly lower tumour burdens and metastasis compared to controls. Furthermore, the spleens and tumours from Ibrutinib-treated mice contained more mature DCs and lower numbers of myeloid-derived suppressor cells (MDSCs), which promote disease progression and are linked to poor prognosis. We also confirmed that ex vivo treatment of MDSCs with ibrutinib switched their phenotype to mature DCs and significantly enhanced MHCII expression. Further, ibrutinib treatment promoted T cell proliferation and effector functions leading to the induction of antitumour T
conclusionsIbrutinib inhibits tumour development and metastasis in breast cancer by promoting the development of mature DCs from MDSCs and hence could be a novel therapeutic agent for the treatment of breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.